PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
about
BKM120 induces apoptosis and inhibits tumor growth in medulloblastomaSingle Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy.Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
P2860
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@ast
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@en
type
label
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@ast
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@en
prefLabel
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@ast
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@en
P2093
P2860
P1433
P1476
PI-3K Inhibitors Preferentiall ...... in SHH Driven Medulloblastoma.
@en
P2093
Alok R Singh
Denise Malicki
Donald L Durden
Guillermo A Morales
John Crawford
Joseph R Garlich
Karen Messer
Michael Alcaraz
Michael L Levy
P2860
P304
P356
10.1371/JOURNAL.PONE.0150836
P407
P577
2016-03-03T00:00:00Z